**Supplementary Table 4**

|  |  |
| --- | --- |
| **Clinical characteristics (n=20)** | |
| **Archival (castration-sensitive) biopsy** | |
| **Histology (N, %)**  Adenocarcinoma | 20, 100% |
| **Gleason score (N, %)**  <7  7  >7  NR | 1, 5%  3, 15%  15, 75%  1, 5% |
| **Metastatic at diagnosis (N, %)**  M0  M1  NR | 7, 35%  12, 60%  1, 5% |
| **Treatment intent (N, %)**  Radical  Palliative | 6, 30%  14, 70% |
| **Paired metastatic castration-resistant biopsy** | |
| **Biopsy site (N, %)**  Bone marrow  Lymph node  Other | 9, 45%  8, 40%  3, 15% |
| **Systemic therapies prior to biopsy^**  1  2  3  4 | 6, 30%  7, 35%  4, 20%  3, 15% |
| **AR targeting therapy prior to biopsy**  Post abiraterone  Post enzalutamide  Post abiraterone and enzalutamide | 9, 45%  7, 35%  4, 20% |

**Clinical characteristics of prostate cancer patients with matched diagnostic (archival) castration-sensitive and metastatic castration-resistant tissue biopsies.**

N – number, NR – not recorded, AR – androgen receptor, ^ - systemic therapies include docetaxel, cabazitaxel, abiraterone and enzalutamide